Treatment of Chronic Lead Intoxication

Letters2 November 1999Treatment of Chronic Lead IntoxicationAna I. Sanchez-Fructuoso, MD, PhD, Dolores Prats, MD, and Alberto Barrientos, MD, PhDAna I. Sanchez-Fructuoso, MD, PhDHospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Sanchez-Fructuoso)Hospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Prats)Hospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Barrientos)Search for more papers by this author, Dolores Prats, MDHospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Sanchez-Fructuoso)Hospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Prats)Hospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Barrientos)Search for more papers by this author, and Alberto Barrientos, MD, PhDHospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Sanchez-Fructuoso)Hospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Prats)Hospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Barrientos)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-9-199911020-00026 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest Lin and colleagues' article (1). In a study of approximately 300 patients, our team showed that a high percentage of patients with gout, hypertension, and chronic renal failure had an excessive body lead burden (2). Six patients with EDTA were treated until urine lead excretion decreased below 150 µg/d. All treated patients progressed to end-stage renal disease, and 3 patients subsequently received kidney transplants. The EDTA mobilization test was done on patients who received transplants, and values greater than 1000 µg of lead per 72-hour urine collection were recorded.An article suggesting that ...References1. Lin JL, Ho HH, Yu CC. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Intern Med. 1999;130:7-13. LinkGoogle Scholar2. Sánchez-Fructuoso AI, Torralbo A, Arroyo M, Luque M, Ruilope LM, Santos JL, et al . Occult lead intoxication as a cause of hypertension and renal failure. Nephrol Dial Transplant. 1996;11:1775-80. CrossrefMedlineGoogle Scholar3. Cory-Slechta D, Weiss B, Cox C. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. J Pharmacol Exp Ther. 1987;243:804-13. MedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Hospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Sanchez-Fructuoso)Hospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Prats)Hospital Clínico Universitario S. Carlos; 28008 Madrid, Spain (Barrientos) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoChelation Therapy for Patients with Elevated Body Lead Burden and Progressive Renal Insufficiency Ja-Liang Lin , Huei-Huang Ho , and Chun-Chen Yu Metrics Cited ByProtective effect of EDTA preadministration on renal ischemiaIncreased Body Lead Burden — Cause or Consequence of Chronic Renal Insufficiency?Erythrocyte aminolevulinate dehydratase activity as a lead marker in patients with chronic renal failure 2 November 1999Volume 131, Issue 9Page: 716KeywordsBoneEthylenediaminetetraacetic acidIntoxicationOsteoclastsOsteoporosisRenal diseasesRenal failureRenal transplantationSteroid therapyUrine Issue Published: 2 November 1999 CopyrightCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...